PTLA didn't say the FDA had actually agreed to a single-trial p<0.01 criterion for approval. (There is no SPA.) Typical biotech-investing scenario where you have to parse management's comments closely.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”